| 生物活性 |
MPT0B098 is a microtubule inhibitor (Ki = 0.8 μM, IC50 = 0.8 μM) that inhibits tubulin polymerization, blocks HuR nucleocytoplasmic transport to reduce HIF-1α mRNA stability, suppresses the HIF-1α, TGF-β/Smad, JAK2/STAT3, and FAK/actin cytoskeleton signaling pathways, upregulates SOCS3 to enhance inhibition of the JAK2/STAT3 pathway, and induces apoptosis, and it can be used for research on various malignant tumors, including head and neck squamous cell carcinoma and human non-small cell lung cancer. |
体外研究 (In Vitro) |
MPT0B098 抑制多种人癌细胞系增殖,包括 H460、A549、H1299、HONE-1、PC-3、KB、HT29 和 MKN-45 细胞,IC50 为 78-150 nM;而 HUVEC 细胞对 MPT0B098 相对不敏感,IC50 为 510 nM。
MPT0B098 抑制微管蛋白聚合,Ki 为 0.8 μM,IC50 为 0.8 μM。
MPT0B098 (0-1000 nM; 24 h) 在 A549 细胞中通过升高 cyclin B1 和 MPM2、改变 Cdc25C 和 Cdc2 磷酸化、增加 TUNEL 阳性细胞、促进 Bcl-2 磷酸化并诱导 PARP 裂解,诱导 G2/M 期阻滞和凋亡。
MPT0B098 (0.2-0.5 μM; 16 h) 抑制 VEGF 诱导的 HUVEC 管腔样结构形成。
MPT0B098 (0.25 μM; 24 h) 抑制 VEGF 诱导的 HUVEC 迁移,且不降低 HUVEC 活力。
MPT0B098 (0-2 μM; 18 h) 浓度依赖性降低 HUVEC 胞内 VEGF 蛋白与上清分泌量;0-0.9 μM MPT0B098 处理 18 h 可抑制缺氧 A549 细胞分泌 VEGF。
MPT0B098 (0-0.9 μM; 18 h) 在缺氧条件下降低 A549 细胞中 HIF-1α 蛋白和 mRNA 水平,降低 HIF-1α mRNA 稳定性,并减少 HuR 从细胞核向细胞质转位。
MPT0B098 (111-444 nM;72 h) 在常氧、缺氧条件下抑制 OEC-M1 细胞增殖,常氧下 IC50 为 222 nM,缺氧下 IC50 为 265 nM。
MPT0B098 (111-444 nM;18 h) 浓度依赖性下调缺氧 OEC-M1 细胞内 HIF-1α 蛋白,阻断缺氧诱发的 F-actin 细胞骨架重构,降低缺氧介导的 FAK 磷酸化,总 FAK 蛋白表达无明显变化。
MPT0B098 (111-444 nM;18-36 h) 抑制缺氧 OEC-M1 细胞内 EMT 转录因子 Twist、SNAI2/Slug 的表达。
MPT0B098 (111-444 nM;36 h) 下调波形蛋白、N-cadherin,同时部分恢复 E-cadherin;抑制 TGF-β 蛋白表达与 Smad2/3 磷酸化,并降低缺氧 OEC-M1 细胞内 TGF-β1、TGF-β2 的 mRNA 水平。
MPT0B098 (111-444 nM;预处理 18 h + TGF-β 共刺激 18 h) 逆转 TGF-β 引发的缺氧 OEC-M1 细胞 Smad2/3 磷酸化。
MPT0B098 (111 nM;48 h) 逆转缺氧诱导的 OEC-M1 细胞间质形态改变。
MPT0B098 (111 nM;4-18 h) 时间依赖性抑制缺氧诱导的 OEC-M1 细胞迁移,且无明显细胞毒性。
MPT0B098 (0.12-0.5 μM;72 h) 浓度依赖性抑制多种口腔鳞状细胞癌细胞系 (OEC-M1、HSC-3、SCC-25、Tu183、DOK、YD-15) 活力,IC50 为 0.14-0.45 μM;正常 HOK 细胞敏感性较低,IC50 为 6.3 μM。
MPT0B098 (0.25 μM;0-60 min) 在 OEC-M1、HSC-3 细胞中诱导时间依赖性微管解聚,洗脱药物 60 min 后微管网络可部分恢复。
MPT0B098 (0.25、0.5 μM;12 h) 剂量依赖性引发 OEC-M1 细胞 G2/M 细胞周期阻滞与 Annexin V 阳性早期凋亡。MPT0B098 (0.12-1 μM;24 h) 上调口腔鳞状细胞癌细胞内活化 caspase-3、活化 PARP,同时下调抗凋亡蛋白 Bcl-2、Mcl-1、Pim-1、Survivin。
MPT0B098 (0.25 μM;15-240 min) 逐步降低 JAK2、TYK2、STAT3 的磷酸化水平与总蛋白表达,不改变 STAT3 mRNA 表达量。
MPT0B098 (0.25 μM;0-60 min) 选择性上调口腔鳞状细胞癌细胞内 SOCS2、SOCS3 蛋白表达,对 PIAS1/3、SOCS1 无上调作用。
MPT0B098 (0.25 μM) 联合 5 μM 顺铂 (MS-E94993) 或 5 μM 5-FU (HY-90006) 对 OEC-M1 细胞的增殖抑制、caspase-3 激活效果显著优。
Cell Cycle Analysis
| Cell Line: |
A549 |
| Concentration: |
75, 150, 300, 450, 600 nM |
| Incubation Time: |
24 h |
| Result: |
Induced G2/M phase arrest in a concentration-dependent manner.
Increased the G2/M phase population with a concomitant loss of the G0/G1 phase, increased cyclin B1 and MPM2 levels, shifted Cdc25C phosphorylation status, and increased hypophosphorylated Cdc2. |
Apoptosis Analysis
| Cell Line: |
A549 |
| Concentration: |
150, 300, 600 nM |
| Incubation Time: |
24 h |
| Result: |
Increased TUNEL-positive apoptotic cells in a concentration-dependent manner.
Increased the TUNEL-positive population from 1% in control cells to 4.9%, 24.7% and 78.7% at 150 nM, 300 nM and 600 nM, respectively.
Induced Bcl-2 phosphorylation and PARP cleavage.
|
Cell Migration Assay
| Cell Line: |
HUVEC |
| Concentration: |
0.25 μM |
| Incubation Time: |
24 h |
| Result: |
Inhibited VEGF-induced HUVEC migration without compromising HUVEC viability. |
Apoptosis Analysis
| Cell Line: |
A549 |
| Concentration: |
0.1, 0.3, 0.6, 0.9, 1.2 μM |
| Incubation Time: |
18 h |
| Result: |
Reduced hypoxia-induced HIF-1α protein expression in a concentration-dependent manner. |
Real Time qPCR
| Cell Line: |
A549 |
| Concentration: |
0.3, 0.6, 0.9 μM |
| Incubation Time: |
24 h |
| Result: |
Reduced HIF-1α mRNA levels under hypoxic conditions, whereas colchicine did not reduce HIF-1α mRNA levels under the same experimental condition. |
Immunofluorescence
| Cell Line: |
A549 |
| Concentration: |
600 nM |
| Incubation Time: |
6, 12, 18 h |
| Result: |
Reduced cytoplasmic HuR distribution and decreased HIF-1α expression under hypoxic conditions. |
Cell Proliferation Assay
| Cell Line: |
OEC-M1 under normoxic /hypoxic conditions |
| Concentration: |
111, 222, 444 nM |
| Incubation Time: |
72 h |
| Result: |
Inhibited OEC-M1 cell proliferation under normoxic and hypoxic conditions, and exerted weaker hypoxia-induced drug resistance. |
Western Blot Analysis
| Cell Line: |
OEC-M1 |
| Concentration: |
111, 222, 444 nM |
| Incubation Time: |
18 h under hypoxia; 36 h under hypoxia; 18 h drug pretreatment + subsequent 18 h TGF-β co-stimulation under hypoxia |
| Result: |
After 18 h hypoxic treatment, dose-dependently downregulated HIF-1α protein, blocked hypoxia-triggered F-actin cytoskeleton rearrangement and reduced hypoxia-induced FAK phosphorylation without changing total FAK protein levels.
After 18 h and 36 h hypoxic treatment respectively, suppressed EMT transcription factors Twist and SNAI2/Slug.
After 36 h hypoxic treatment, downregulated mesenchymal markers vimentin and N-cadherin, partially restored epithelial marker E-cadherin, decreased TGF-β protein expression and inhibited Smad2/3 phosphorylation.
After 18 h hypoxic drug pretreatment followed by another 18 h TGF-β co-stimulation under hypoxia, reversed TGF-β-triggered Smad2/3 phosphorylation in hypoxic OEC-M1 cells.
|
Real Time qPCR
| Cell Line: |
OEC-M1 under hypoxic conditions |
| Concentration: |
111, 222, 444 nM |
| Incubation Time: |
36 h |
| Result: |
Decreased mRNA transcription levels of TGF-β1 and TGF-β2 in hypoxic OEC-M1 cells. |
Immunofluorescence
| Cell Line: |
OEC-M1 under hypoxic conditions |
| Concentration: |
111nM |
| Incubation Time: |
48 h |
| Result: |
Reversed hypoxia-induced mesenchymal fibroblast-like morphological transformation of OEC-M1 cells. |
Cell Migration Assay
| Cell Line: |
OEC-M1 under hypoxic conditions |
| Concentration: |
4 h, 6 h, 8 h, 18 h |
| Incubation Time: |
48 h |
| Result: |
Time-dependently inhibited hypoxia-induced OEC-M1 cell migration without obvious cytotoxicity, and its anti-migration activity was superior. |
Cell Cycle Analysis
| Cell Line: |
OEC-M1 |
| Concentration: |
0.25 μM, 0.5 μM |
| Incubation Time: |
12 h |
| Result: |
Induced dose-dependent G2/M phase cell cycle arrest in OEC-M1 cells. |
Apoptosis Analysis
| Cell Line: |
OEC-M1, HSC-3, DOK, YD-15 |
| Concentration: |
0.12 μM, 0.25 μM, 0.5 μM, 1 mM |
| Incubation Time: |
24 h |
| Result: |
Induced concentration-dependent cell apoptosis.
Elevated activated caspase-3 and cleaved PARP.
Downregulated anti-apoptotic proteins including Bcl-2, Mcl-1, Pim-1 and Survivin.
|
Western Blot Analysis
| Cell Line: |
OEC-M1, HSC-3 |
| Concentration: |
0.25 μM |
| Incubation Time: |
15 min, 30 min, 60 min, 120 min, 240 min |
| Result: |
Time-dependently decreased phosphorylation and total protein levels of JAK2, TYK2 and STAT3 without altering STAT3 MRNA.
Selectively upregulated SOCS2 and SOCS3 protein while SOCS1, PIAS1 and PIAS3 kept stable expression.
Prolonged the half-life of SOCS3 protein, strengthened the binding between SOCS3 and JAK2/TYK2, and promoted the ubiquitination and degradation of JAK2 and TYK2.
|
Cell Cytotoxicity Assay
| Cell Line: |
OEC-M1 |
| Concentration: |
0.25 μM |
...(内容过长已截断)
体内研究 (In Vivo) |
MPT0B098 (25, 50 mg/kg; 腹腔注射; 每日一次; 连续 5 天) 在 A549 人非小细胞肺癌移植瘤裸鼠模型中抑制肿瘤生长并降低微血管密度。
| Animal Model: |
Five-week-old nude mice subcutaneously implanted with A549 cells (2 × 106 cells) into the right flank region |
| Dosage: |
25, 50 mg/kg |
| Administration: |
Intraperitoneal injection (i.p.); once daily; for 5 consecutive days |
| Result: |
Intraperitoneal injection (i.p.); once daily; for 5 consecutive days
Delayed A549 xenograft tumor growth in a dose-dependent manner.
Reduced CD31-positive microvessel density in tumor specimens.
Was well tolerated up to 50 mg/kg.
Caused no obvious signs of toxicity in drug-treated mice.
Maintained body weight loss within 15% in all treatment groups.
|
|
| 分子量 |
366.44 |
| 分子式 |
C20H18N2O3S |
| CAS No. |
1254363-89-7 |
| 储存方式 |
Please store the product under the recommended conditions in the Certificate of Analysis. |
| 运输条件 |
Room temperature in continental US; may vary elsewhere. |
动物实验计算换算器
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:
比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。
-
客服
2851296953
18923798467
微信洽谈
|